Zynga, Inc. Fourth-Quarter Earnings and Sales Topped Wall Street Estimates
NEW YORK, February 7, 2013 /PRNewswire/ –
Zynga reported fourth-quarter earnings and sales late Tuesday, revealing that the
Company earned 1 cent per share, or $6.9 million, on sales of $311 million last quarter.
Analysts polled by Thomson Reuters expected a loss of 3 cents per share and $212 million
in revenue. The Company’s tally of daily active users rose to 56 million in the fourth
quarter of 2012 meaning 2 million new daily active users were added in the last year.
Whether bull or bear The Stock Freak has got you covered! Sign up to receive our free
newsletters and stay up to date with stocks on the run. http://www.TheStockFreak.com
Elan Corporation, plc (NYSE: ELN) – ELN shares closed down 10.23% yesterday at $9.39.
The stock was one of the biggest losers on the NYSE on Wednesday even though the Company
released strong fourth quarter and full-year 2012 financial results yesterday. Full Year
2012 guidance was met; Pro-forma Revenues up 13%; Adjusted EBITDA was up 31%. Elan
Corporation, plc operates as a neuroscience-based biotechnology company in the United
States, Ireland, and internationally. It engages in research, development, and commercial
activities primarily in the areas of Alzheimer’s disease, Parkinson’s disease, and
multiple sclerosis (MS). The company offers Tysabri, an alpha-4 integrin inhibitor
primarily for the treatment of MS. Biogen Idec Inc. has agreed to buy partner Elan Corp’s
stake in the Tysabri multiple sclerosis medicine for $3.25 billion in cash plus future
royalties. The number of patients taking Tysabri grew by 12% in 2012. At 63,059,803 shares
traded yesterday, volume was roughly thirty times higher than average.
BlackBerry (Nasdaq: BBRY) – shares of BlackBerry closed in the green for the 5th
trading day in a row yesterday. The stock modestly closed up 0.19% on Wednesday on volume
almost double the stock’s average. Trading volume yesterday was 100,212,704 shares.
BlackBerry has been one of the most active stocks on the Nasdaq recently. The Company
launched two new phones last week, the Z10 and the Q10, both running a new operating
system called BB10. BlackBerry said on Wednesday that the Canadian and U.K. launches of
the Z10 have been the best of any of its handsets debuts in those regions ever. The Z10
will not be in stores in the United States until an unspecified point in March.
The Walt Disney Company (NYSE: DIS) – shares of DIS hit a new 52-week high of $55.50
on Wednesday after the Company released positive first-quarter earnings results. The
company reported $0.79 earnings per share for the quarter, beating the consensus estimate
of $0.77 by $0.02. The company had revenue of $11.34 billion for the quarter, compared to
the consensus estimate of $11.21 billion. The Company’s revenue was up 5.2% compared to
the same quarter last year. DIS was one of the most active stocks traded on the NYSE
yesterday. The Company also announced they will be expanding the Star Wars Franchise and
will create two Star Wars spinoffs.
Vocus Inc. (Nasdaq: VOCS) – Vocus Inc. was one of the biggest losers in the Nasdaq
yesterday, dropping 13.64% at the close. The stock closed at $15.32 but went as low as
$13.48 on Wednesday. VOCS traded 1,680,508 shares yesterday, a big increase from its
average of 129,069 shares. The Company had strong Q4 earnings, but issued discouraging
guidance for 2013 including the year’s first quarter. For the first quarter, Vocus is
projecting revenue of $46.3 million to $46.7 million and non-GAAP profits of 9-10 cents a
share; Street consensus had been $49 million and 13 cents.
BIOLASE, Inc. (Nasdaq: BIOL) – BIOL shares saw a big boost on Wednesday closing at
$3.38, up $0.55 (19.43%). The stock hit a new 52-week high yesterday of $3.93 on trading
volume over three million shares compared to an average of 98,519. The U.S. Food and Drug
Administration (FDA) has cleared the Company’s 940nm Diolase 10 diode soft tissue laser
for use in 19 additional medical markets including: ear, nose and throat, oral surgery,
arthroscopy, gastroenterology, general surgery, dermatology, plastic surgery, podiatry,
GI/GU, gynecology, neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery,
thoracic surgery, urology, dermatology, aesthetics, and vascular surgery. BIOLASE, Inc. is
the world’s leading manufacturer and distributor of dental lasers.
To find similar research reports that are available for free follow the link below and
sign up at http://www.TheStockFreak.com [http://www.thestockfreak.com/index2.html ]
Disclosure: TheStockFreak.com is not a registered investment advisor and nothing
contained in any materials should be construed as a recommendation to buy or sell
securities. Investors should always conduct their own due diligence with any potential
investment. Please read our report and visit our website, for complete risks and